2024
Weekly Bortezomib Decreases Rates of Peripheral Neuropathy without Diminishing Efficacy As Compared to Twice Weekly Bortezomib in Combination with Lenalidomide, Dexamethasone and Daratumumab
Yi I, Gaspar E, Eighmy W, Roeder H, Bar N. Weekly Bortezomib Decreases Rates of Peripheral Neuropathy without Diminishing Efficacy As Compared to Twice Weekly Bortezomib in Combination with Lenalidomide, Dexamethasone and Daratumumab. Blood 2024, 144: 7004-7004. DOI: 10.1182/blood-2024-199190.Peer-Reviewed Original ResearchTwice-weekly bortezomibTwice-weekly groupTwice-weekly dosingWeekly bortezomibMultiple myelomaPeripheral neuropathyBortezomib doseTwice-weeklyFrontline treatmentRate of PNDay 1Rates of peripheral neuropathyMedian follow-up timeTreatment efficacyBortezomib-induced peripheral neuropathyResponse rateWeeks groupBortezomib dose reductionBortezomib-containing regimensBortezomib-induced PNDose of bortezomibDiagnosis of MMIncidence of PNSingle-center studyFollow-up timeP-377 Impact of Weekly Versus Twice Weekly Bortezomib on Rates of Peripheral Neuropathy in Combination With Lenalidomide, Dexamethasone and Daratumumab
Yi I, Gaspar E, Eighmy W, Roeder H, Bar N. P-377 Impact of Weekly Versus Twice Weekly Bortezomib on Rates of Peripheral Neuropathy in Combination With Lenalidomide, Dexamethasone and Daratumumab. Clinical Lymphoma Myeloma & Leukemia 2024, 24: s251. DOI: 10.1016/s2152-2650(24)02279-1.Peer-Reviewed Original Research
2021
Cost-effectiveness of once-weekly selinexor, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma
Patel KK, Parker T, Di M, Bar N, Huntington SF, Giri S. Cost-effectiveness of once-weekly selinexor, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma. Leukemia & Lymphoma 2021, 62: 2777-2784. PMID: 34151696, DOI: 10.1080/10428194.2021.1933477.Peer-Reviewed Original ResearchConceptsIncremental cost-effectiveness ratioRefractory multiple myelomaMultiple myelomaWeekly selinexorR Multiple MyelomaProgression-free survivalUS payer perspectiveCost-effectiveness ratioWeekly bortezomibTreatment strategiesPayer perspectiveLifetime horizonIncremental effectivenessBortezomibIncremental costMyelomaDexamethasoneSelinexorQALYVDPatients